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Mebendazole is an important medicine used to treat helminth infections. These infections affect more 
than two billion people worldwide. The LAFEPE® (Recife-PE, Brazil) produces the drug mebendazole 
oral suspension that contains the preservatives methylparaben and propylparaben in its formulation. 
Drugs that have antimicrobial properties due to preservatives must undergo neutralization of these 
compounds to allow microbial count testing according to recommendations by the official compendia. 
In order to obtain a validated method for microbial counting and to ensure its safety and reliability within 
the pharmaceutical industry,  validation of preservative neutralization and of the method for microbial 
counting was performed according to the USP 30 and PDA Technical Report No. 33. The method used 
ATCC Gram positive and Gram negative microorganisms, yeasts, most and culture media Tryptic Soy 
Agar and Sabouraud dextrose agar. The neutralizers were polysorbate 80 and lecithin. Recovery levels 
of over 70% of the microorganisms used in the test indicated the neutralization of antimicrobial activity 
and proved the absence of toxicity of neutralizers. The microbial counting method validated proved 
accurate, precise, robust and linear and can be safely used in routine operations.
Uniterms: Mebendazole/oral suspension. Microbial count.
O mebendazol é um importante medicamento utilizado no tratamento de infecções por helmintos. Essas 
infecções afetam mais de dois bilhões de pessoas em todo o mundo. O LAFEPE (Recife-PE, Brasil) produz 
o medicamento mebendazol suspensão oral, que possui em sua formulação os conservantes metilparabeno 
e propilparabeno. Em medicamentos que possuem propriedades antimicrobianas em decorrência dos 
conservantes faz-se necessária a neutralização da ação desses compostos para a realização do teste de 
contagem microbiana segundo preconizado pelos compêndios oficiais. A fim de obter um método de 
contagem microbiana validado e que garanta sua segurança e reprodutibilidade dentro da indústria 
farmacêutica foi realizada a validação da neutralização dos antimicrobianos e validação do método de 
contagem microbiana de acordo com a USP 30 e PDA-Technical Report N° 33. O método desenvolvido 
utilizou microrganismos ATCC Gram positivos, Gram negativos, leveduras e fungos e meios de cultura 
Tryptic Soy Agar e Sabouraud-dextrose Agar. Os neutralizantes foram polissorbato 80 e lecitina de soja . 
Níveis de recuperação superiores a 70% dos microrganismos utilizados no ensaio indicaram neutralização 
da atividade antimicrobiana e comprovou a ausência de toxicidade dos neutralizantes. O método de 
contagem microbiana validado revelou-se exato, preciso, robusto e linear podendo ser utilizado com 
segurança na rotina operacional. 
Unitermos: Mebendazol/suspensão oral. Contagem microbiana.
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INTRODUCTION
Scientific and technological advances in recent 
decades have enabled better development and control of 
drugs, universally determining the minimum efficacy, 
safety and quality requirements of medicines (Carvalho 
et al., 2004; Bomblies, Weiss, Beckmann, 2007). Drug 
quality is related to the degree of compliance with such 
requirements and minimum standards determined by 
official standards. To ensure these requirements are met it 
is necessary to perform physical, chemical and biological 
tests (Itah, Udokpoh, Ofum, 2004).
In order to ensure the microbiological quality of me-
bendazole oral suspension 20mg/mL, microbiological tests 
should be performed, among them the microbial counting 
test advocated by both the Brazilian Pharmacopoeia IV 
edition and the USP 30 (Bou-Chacra, 2003; F.Bras. IV, 
1988; USP, 2007).
Methods of microbial counting seek to assess the total 
number of bacteria, yeasts and most using specific culture 
media. This method includes a series of validations, such as: 
neutralization of antimicrobial agents, recovery of test mi-
croorganisms and the microbial counting method itself. The 
USP 30 and PDA Technical Report No. 33 describe which 
key precision, accuracy, robustness and linearity parameters 
are to be observed in this validation. In addition, another 
important factor is that the method implemented is validated 
for each product analyzed (USP, 2007; Ramos, 2010). 
In this study, mebendazole oral suspension 20 mg/
mL produced by the LAFEPE Laboratory (Pharmaceutical 
Laboratory of Pernambuco Governor Miguel Arraes S/A) 
was investigated. Mebendazole is one of most widely 
used anthelmintic drugs (Goodman and Gilman, 2006) 
and classified by the World Health Organization (WHO) 
as an essential medicine based on its clinical efficacy, low 
cost and ease of administration (Agatonovic-Küstrin et al., 
2008). This drug belongs to the class of benzimidazole 
derivatives which includes albendazole and thiabendazole. 
It has a broad spectrum of activity, acting on cestodes and 
nematodes parasites. (Bennett, Guyatt, 2000).
Mebendazole  oral suspension 20 mg/mL produced 
by the LAFEPE laboratory is a non-sterile product con-
taining parabens preservatives in its formulation at the 
proportions of 0.06% propylparaben (w/v) and 0.16% 
methylparaben (w/v). The antimicrobial system used in 
the manufacturing of mebendazole oral suspension is 
important to ensure the stability and safety of the pro-
duct with respect to microbiological purity, in addition 
to protecting the user from any health compromise due 
to product contamination. This is no substitute however, 
for the good manufacturing practices inherent in the ma-
nufacturing process of pharmaceutical industries (Pinto, 
Kaneko, Ohara, 2003; Russell, 2003). The conducting of 
a validation test for antimicrobial agent neutralization and 
for microbial counting method validation thus become key 
factors that will prove the method’s effectiveness in reco-
vering product contaminants. This is necessary since the 
presence of preservatives may promote microbial growth 
inhibition, thereby preventing the determination of total 
number of colonies present in the sample. Furthermore, 
immune-compromised patients who make use of oral 
drugs may experience an aggravated clinical condition 
if these products are microbiologically contaminated. In 
addition to the objectives outlined is the review of the 
scarce scientific publications dealing with the subject and 
their application in pharmaceutical industries.
MATERIAL AND METHODS
Substances and culture media
To validate the microbial counting method, poly-
sorbate 80 (Oxiteno® - Lot 16 506), soy lecithin (Inlab® 
- Lot 832490), sodium chloride solution, 0.9% (Fresenius 
Kabi® - Lot 040 702 059), Soybean casein broth (Difco® 
- Lot 8150627), casein soy agar (Difco® - Lot 9160882, 
Merck® -Lot VM803358714 and Oxoid® - Lot 463341), 
Sabouraud dextrose agar (Difco® - Lot 6319541, Mer-
ck® - Lot VM804238723 and Oxoid® - Lot 476969), and 
Sabouraud dextrose broth (Difco® - Lot 6269292, Merck® 
- Lot VM462926 and Oxoid® - Lot 455812) were used.
The dosage form used was mebendazole (oral 
suspension 20 mg/mL – Lot 09120754) produced by the 
LAFEPE® (Pharmaceutical Laboratory of Pernambuco 
Governor Miguel Arraes).
Test microorganisms
For microbiological tests, the microorganisms 
described in the official compendia F. Bras. IV and USP 
30 (2007): Aspergillus niger ATCC 16404 (Cefar® - Lot 
CBC295), Candida albicans ATCC 10231 (Cefar® - Lot 
CBH360), Escherichia coli ATCC 8739 (Cefar® - Lot 
CBI370), Pseudomonas aeruginosa ATCC 9027 (Cefar® - 
Lot CBE322), Staphylococcus aureus ATCC 6538 (Cefar® 
- Lot CBJ383) were employed.
Preparation of microbial suspension and inoculum 
standardization
From the stock cultures in casein soy agar, bacteria 
were transferred with the aid of a platinum loop calibrated 
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at 10 µL onto 5 mL soybean casein broth liquid medium. 
These cultures were incubated for 18-24 hours at 32 ± 2 °C. 
Serial dilutions in 0.9% sodium chloride solution were 
carried out and the last three were plated and incubated 
for 24 hours at 32 ± 2 °C and listed in order to obtain a 
standardized microbial suspension to 10² CFU/mL. For 
yeasts and most standardization, a similar methodology to 
that for bacteria was used, except for the media employed 
which were liquid and solid Sabouraud-dextrose. The 
transfer of Aspergillus niger culture was facilitated by 
suspending spores in 2 mL 0.9% sodium chloride solution 
added to 0.05% polysorbate 80 solution. These cultures 
were incubated at 22 ± 2 °C for 48 hours or 96 hours for 
Candida albicans and Aspergillus niger, respectively.
Validation of preservative neutralization
Based on the drug formulation, chemical neutrali-
zation using 0.4% polysorbate 80 (Tween® 80) (w/v) and 
0.5% soy lecithin (w/v) was chosen, as recommended by 
the official compendia (F. Bras. IV, 1988; USP, 2007) and 
1:10 dilution (v/v) was used for the water soluble products.
Determining the efficacy and toxicity of the neu-
tralizer is required to ensure the validation process of 
antimicrobial agent neutralization. 
This is observed through microorganism recovery 
in different groups for analysis: test (T), peptone (P) and 
viability (V) (USP, 2007). The comparison between the 
test group and peptone group demonstrates neutralization 
effectiveness, whereas the comparison between the pepto-
ne group and viability group demonstrates neutralization 
safety i.e. that it has no toxicity.
These tests were performed in quintuplicate and the 
criterion used to demonstrate  neutralization validation 
was as recommended by the 2007 USP, which determines 
the recovery of test microorganisms to be greater than or 
equal to 70%.
Preparation of analysis groups
The test group (T) and peptone (P) are composed of 
90 mL casein soy broth supplemented with 0.4% polysor-
bate 80 (w/v) and 0.4% soy lecithin (w/v), and 10 mL drug 
or 10 mL 0.9% sodium chloride, respectively. The viability 
group (V) comprises casein soy broth only (100 mL).
From the analysis groups, 1.0 mL aliquots were 
taken and deposited in sterile Petri dishes concomitantly 
with 0.3 or 1.0 mL of standardized suspension of test 
microorganisms. Subsequently, about 17 ± 2 mL of solid 
soy casein or Sabouraud dextrose media was poured and 
the contents homogenized. Petri dishes remained on a 
flat surface until complete medium solidification. Subse-
quently, plates were incubated at 32 ± 2 °C for 48 hours 
for bacteria and 22 ± 2 °C for 48 hours or 96 hours for 
Candida albicans and Aspergillus niger, respectively. The 
reading was performed after this period by counting the 
colonies using a digital counter (Quimis ®) and the results 
expressed in colony forming units/plate.
Development and validation of microbial counting 
method
The microbial counting method was validated ac-
cording to the parameters: precision, accuracy, linearity 
and robustness recommended by the USP-30 and PDA 
Technical Report No. 33.
Precision was evaluated at two levels: repeatability 
(intra-run precision, n = 5) and intermediate precision 
(inter-run precision, n = 5 per analyst). The repeatabi-
lity and intermediate precision were evaluated in the 
three groups for analysis (test, peptone and viability) 
with two levels of microbial incrimination, one with a 
10-30 CFU/plate and the other with a 30-300 CFU/plate.
The criterion used to prove the accuracy of the me-
thod at the level of repeatability was as  recommended by 
USP 30, which determines a maximum variation coeffi-
cient of 25% or 15% when groups are incriminated with 
10-30 CFU/plate or 30-300 CFU/plate, respectively. Data 
obtained for the intermediate precision were statistically 
analyzed by ANOVA (Neto, Scarmino, Bruns, 2001). The 
accuracy was assessed by comparing the values obtained 
for test microorganism recovery in the test (T), peptone (P) 
and viability (V) groups. To achieve this, fixed volumes 
of 0.3 mL and 1.0 mL of microorganism suspension stan-
dardized  in 10² CFU/mL were used to frame the analysis 
groups, thus achieving incrimination levels of 10-30 CFU/
plate and 30 - 300 CFU/plate.
The criterion used to prove the accuracy of the 
method recommended by USP 30 determines test micro-
organisms recovery of less than 70%.
The linearity of the method was verified through the 
correlation among different volumes (0.2, 0.4, 0.6, 0.8, 1.0 
and 1.2 mL) which were taken from the analysis groups 
(Test, Peptone and Viability) and their corresponding Co-
lony Forming Units. The results were statistically analyzed 
by calculating the linear regression using the minimum 
squares method and curves whose linear correlation (R ²) 
was at least 0.95 (USP, 2007) were considered satisfactory.
The robustness parameter was evaluated through 
the application of small changes to the microbiological 
method conditions. This was performed by using  casein 
soy agar and Sabouraud dextrose agar media from three 
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different laboratories (Difco®, Merck® and Oxoid®) and 
incubating at different temperatures for yeast and most 
(22 ± 2 °C and 30 ± 2 °C) and bacteria (30 ± 2 °C and 
35 ± 2 °C) and by varying sodium polysorbate 80 neutra-
lizing concentration from 0.4% to 3% in casein soy broth. 
These tests were performed in triplicate and the results 
were evaluated by analysis of variance (ANOVA) (Neto, 
Scarmino, Bruns, 2001).
Microbial count of medicine
After validation of the medicine’s microbial counting 
method and after  preservative neutralization, a count of 
bacteria and most that would possibly grow under aerobic 
conditions was performed. This was done by  incorporating 
10.0 mL of mebendazole oral suspension in 90.0 mL soy-
bean casein broth with the addition of neutralizing agents 
0.4% sodium polysorbate 80 (w/v) and 0.5% soy lecithin 
(w/v) (1:10). 1.0 mL aliquots of this preparation were 
placed in Petri dishes and then 17 ± 2.0 mL of casein soy 
agar or Sabouraud dextrose agar solid media was poured. 
The plates were homogenized, their contents solidified and 
then incubated at 32 ± 2 °C for 48 hours for bacteria and 
22 ± 2 °C for 48 hours to 96 hours for yeasts and most. After 
this period colony counting was performed using a digital 
counter (Quimis ®) and results expressed in CFU/mL.
Evaluation of microbial growth and sterility of 
culture media
Liquid and solid casein soy media and Sabouraud-
dextrose solid medium were used to evaluate test micro-
organisms’ growth. These media were inoculated with 
10² CFU/mL and incubated at 32 ± 2 °C for 48 hours for 
bacteria and 22 ± 2 °C for 48 hours for yeasts and 96 for 
most. Parallel to this assessment, media sterility and purity 
of microbial cultures were observed.
RESULTS AND DISCUSSION
Validation of preservative neutralization
Neutralization effectiveness was observed by the 
high recovery percentage in the test group which ranged 
from 90.95% to 99.72% for mebendazole oral suspension 
20 mg/mL. Along with recovery determination, the non-
toxicity of neutralizers was confirmed by the recovery ra-
tes of microorganisms in the peptone group which ranged 
from 93.53% to 103.82% (Table I).
During the validation process of microbiological 
methods,  microorganism variability should be taken 
into account (USP, 2007). Three sources of variation are 
commonly present: the distribution error of samples, the 
cellular morphology and metabolic activity of microorga-
nisms. It is known that microorganism distribution occurs 
heterogeneously. During laboratory tests, it must be assu-
med that the product was produced under homogeneous 
conditions because only then is it possible to extrapolate 
results (PDA, 2000). From values obtained,  analysis 
groups showed percentage values of test microorganism 
recovery to lie within pharmacopoeial standards, showing 
a homogeneous distribution of these cells with 95% confi-
dence of accuracy, whereas Student’s t test revealed no di-
fference for the values obtained between test and peptone 
TABLE I - Neutralization Evaluation of preservative for Mebendazole Oral Suspension 20 mg/mL by LAFEPE® with three analysis 
groups: viability (V), peptone (P) and test (T), and respective values for ttabulated and tcalculated with 95% accuracy
Microorganisms UFC/plate
Analysis Groups
V(X) T(X) %R ttab tcalc P(X) %R ttab tcalc
Aspergillus niger 
ATCC 16404
10-30 19.00 17.40 93.55
2.77
2.35 18.60 97.89
2.77
2.44
30-300 72.20 71.00 99.72 1.41 71.20 98.61 0.13
Candida albicans 
ATCC 10231
10-30 43.0 37.80 92.64 2.52 40.80 94.00 2.02
30-300 125.60 123.20 99.52 0.79 123.80 98.57 0.26
Escherichia coli 
ATCC 8739
10-30 48.00 46.00 98.71 0.64 46.60 97.08 0.36
30-300 152.80 149.00 97.13 0.36 153.40 100.39 0.95
Pseudomonas aeruginosa
ATCC 9027
10-30 19.00 18.20 96.81 0.66 18.80 98.94 1.17
30-300 99.20 96.20 97.96 1.75 98.20 98.99 0.91
Staphylococcus aureus 
ATCC 6538
10-30 40.20 34.20 90.95 1.17 37.60 93.53 1.49
30-300 130.80 130.40 96.02 1.63 135.80 103.82 1.36
CFU=Colony Forming Units, X= quintuplicate average, %R=recovery percentage
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TABLE II - Repeatability values obtained of microbial counting method for mebendazole oral suspension 20 mg/mL LAFEPE® 
with two levels of incrimination among three analysis groups: viability (V), peptone (P) and test (T)
Microorganisms Levels of Incrimination Analysis groups (CV%)
CFU/plate V P T
Aspergillus niger  ATCC 10-30 14.89 14.43 15.02
30-300 9.76 11.56 9.50
Candida albicans ATCC 10-30 16.66 13.80 6.59
30-300 1.83 6.99 2.88
Escherichia coli ATCC 10-30 10.10 15.52 9.22
30-300 3.96 2.24 5.69
Pseudomonas aeruginosa ATCC 10-30 13.99 15.25 11.53
30-300 6.55 5.26 2.80
Staphylococcus aureus ATCC 10-30 14.88 4.34 21.36
30-300 2.72 4.37 4.49
CFU=Colony Forming Units, CV%=Coefficient of Variation 
groups, as well as between peptone and viability groups.
Cell morphology is also a point that warrants consi-
deration (USP, 2007). Microorganisms exhibit a variety of 
morphologies during their formation in colonies that may 
occur singly or in pairs, tetrads or irregular clusters. Some 
microorganisms have the ability to form biofilms, which 
will also affect results. The number of colony forming 
units formed by plates directly affects the colony morpho-
logy and precision of cell counts (PDA, 2000 ). The USP 
30 states that recovery of test microorganisms must be 
greater than or equal to 70%. Thus, it can be observed that 
results are in accordance with pharmacopoeial standards.
The nature of contaminant microorganisms and 
microbiological variability exert a strong effect on the 
response to the antimicrobial agent and the neutralization 
required in recovery (USP, 2007). The validation process 
of neutralization of antimicrobial agents showed adequate 
recovery of bacteria, most and yeasts with maximum in-
crimination values of 10 ² CFU/mL, confirming that these 
microorganisms were not inhibited by the test sample, 
mebendazole, or by the neutralization system consisting 
of 0.4% polysorbate 80 and 0.5% soy lecithin (Kampf , 
Shaffer, Hunte, 2005; Kratzer et al., 2006). As shown, the 
efficacy and toxicity of the neutralizer was confirmed by 
the recovery rates greater than 70% in the test and peptone 
groups, respectively, thereby assuring the efficiency of 
method.
Development and validation of microbial counting 
method
The microbial counting method proved accurate on 
both parameters. Accuracy is defined by USP 30 as the 
degree of data approximation obtained in the analysis. Pre-
cision is usually expressed by relative standard deviation 
(RSD) or coefficient of variation (CV%). In the repeata-
bility parameter, the three analysis groups inoculated with 
two different microorganism concentrations (10-30 CFU/
plate and 30-300 CFU/plate) had lower coefficients of 
variation than those recommended by USP (Table II). 
This compendium allows for up to 25% variation in 
microbial recovery for inoculations of test organisms at 
10-30 CFU/plate and 15% for the range of 30-300 CFU/
plate. For intermediate precision (Table III), no statistically 
significant differences were evident between the results of 
microorganism recovery done by two different analysts. 
The F values calculated were lower than the tabulated F 
values, confirming with 95% confidence that the method 
is accurate.
The accuracy of the method was demonstrated 
through two levels of incrimination, 10-30 CFU/plate 
and 30-300 CFU/plate. The test accuracy was attained by 
comparing the CFU/plate of the test and peptone groups 
with the viability group (control group). There was no 
significant difference in the recovery of test microorga-
nisms between peptone and test groups when compared 
to viability (p ≤ 0.05). The recovery percentages for the 
two levels of microbial incrimination were greater than 
70% (Table IV). These data are consistent with the limits 
set forth by the USP 30, establishing that the microbiolo-
gical recovery must be less than 70%. The method was 
therefore accurate, as confirmed by Student’s t test, since 
no significant differences were found between obtained 
(t cal) and expected (t tab) values (p ≤ 0.05).
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TABLE III – Values obtained on Determination of Intermediate Precision of  microbial counting method done by two different 
analysts for Mebendazole Oral Suspension 20 mg/mL LAFEPE® with two levels of incrimination among three analysis groups: 
viability (V), peptone (P) and test (T) and respective values for Ftabulated and Fcalculated with 95% accuracy
Microorganisms Analyst
Levels of Incrimination
10 - 30 CFU/plate (X±SD) 30 - 300 CFU/plate (X±SD)
V P T F tab F cal V P T F* tab F* cal
Aspergillus niger 
ATCC 16404
1 20.20  ±  3.35 20.40  ±  2.97 20.60  ±  3.44
2.62
0.78
79.00  ±  1.58 78.80  ±  3.96 77.80  ±  2.77
2.62
2.43
2 19.00 ±  2.83 17.40  ±  2.51 18.60  ±  2.79 72.20 ±  7.50 71.20  ±  8.23 71.00  ±  6.75
Candida albicans ATCC 
10231
1 33.40  ±  7.23 25.00  ±  4.66 38.40  ±  5.22
1.71
131.20  ±  7.19 128.00  ±  6.71 128.40  ±  9.40
1.01
2 43.40  ±  7.23 40.80  ±  5.63 37.80  ±  2.49 125.60  ±  2.30 123.20  ±  8.61 123.80  ±  3.56
Escherichia coli  
ATCC 8739
1 52.08  ±  6.38 51.80  ±  6.53 44.20  ±  2.77
1.86
160.80  ±  8.98 151.80  ±  7.33 147.40  ±  8.14
2.02
2 48.00  ±  4.85 46.60  ±  7.23 46.00  ±  4.24 152.80  ±  6.06 153.40  ±  3.44 149.00  ±  8.49
Pseudomonas 
aeruginosa ATCC 9027
1 19.60  ±  4.39 20.40  ±  3.51 16.20  ±  1.79
1.21
89.60  ±  13.16 97.00  ±  3.67 96.20  ±  3.11
0.84
2 17.80  ±  2.49 18.20  ±  2.77 18.80  ±  2.17 96.20  ±  6.30 98.20  ±  5.17 99.20  ±  2.77
Staphylococcus aureus 
ATCC 6538
1 37.20  ±  4.87 36.40  ±  3.58 45.40  ±  9.48
1.95
138.20  ±  6.61 138.80  ±  6.76 137.40  ±  7.89
1.78
2 37.60  ±  5.59 34.20  ±  1.48 40.20  ±  8.58 130.80  ±  3.56 135.80  ±  5.93 130.40  ±  5.86
CFU = Colony Forming Units; X =  quintuplicate average, SD = standard deviation
TABLE IV - Values obtained for Accuracy of microbial counting method for Mebendazole Oral Suspension 20 mg/mL LAFEPE® 
with two levels of incrimination among three analysis groups: viability (V), peptone (P) and test (T), and respective values for 
ttabulated and tcalculated with 95% accuracy
Microorganisms
Levels of Incrimination
10 - 30 CFU/plate 30 - 300 CFU/plate
%R t tab t cal %R t tab t cal
Aspergillus niger ATCC 16404 V 100.00
2.77
100.00
2.77
P 91.58 2.35 98.61 1.41
T 97.89 1.63 98.34 1.17
Candida albicans ATCC 10231 V 100.00 100.00
P 94.01 2.52 98.09 0.79
T 87.10 2.48 98.57 1.72
Escherichia coli ATCC 8739 V 100.00 100.00
P 98.11 0.64 100.39 0.36
T 83.71 1.36 97.51 0.63
Pseudomonas aeruginosa ATCC 9027 V 100.00 100.00
P 102.25 0.66 102.08 1.75
T 105.62 1.11 103.12 1.76
Staphylococcus aureus ATCC 6538 V 100.00 100.00
P 90.96 1.17 103.82 1.63
T 106.91 1.51 99.69 0.30
CFU = Colony Forming Units, % R = percentage recovery on comparison of test microorganisms
The microbial count is influenced by metabolic acti-
vity, genotype and microorganism distribution for growth. 
During the analysis, microorganisms may be stressed due 
to environmental conditions or inhibitory components of 
the formulation itself, thus reducing the method accuracy. 
It may be noted that peptone recovery values of over 100% 
were found, where this may be due to microbial variability. 
Regarding the values over 100% in the test group, these 
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may be due to the use of neutralizing agents that can inac-
tivate some products that cause stress to cells. Similarly, 
the mebendazole may contain sufficient nutrients to ensure 
the survival of microorganisms or maintenance of their 
growth rates.
The method’s linearity was demonstrated by the 
proportional relationship between the number of colony 
forming units detected in the three analysis groups and 
their volumes taken (0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mL). The 
values of correlation coefficients (R²) ranged from 0.9694 
to 0.9932 for the oral suspension of mebendazole (Table 
V). These values are consistent with values established by 
the USP 30, which determines R²> 0.95. No statistically 
significant correlation of the linear coefficients obtained 
for the three analysis groups was found (p ≤ 0.05).
A method is considered robust when it has the abi-
lity to provide unchanged results even when subjected to 
changes. Robustness is the parameter that most closely 
matches the laboratory reality since it evaluates the results 
under different conditions of analysis showing the values 
that can be acceptable in the face of changing conditions 
of analysis.
Given the change of parameters such as temperature, 
concentration of sodium polysorbate 80 and culture me-
dia, the results of microbial counts were not statistically 
different from those obtained under conditions defined as 
standard (p ≤ 0.05) (Table VI).
Microbial count of medicine
The microbial count test was performed for Me-
bendazole oral suspension 20 mg/mL - LAFEPE® and no 
viable cells were recovered.
Test of microbial growth promotion and sterility 
of culture media
The culture media used in this experiment proved 
its ability to promote microbial growth under the test 
conditions. The sterility test showed absence of viable 
microorganisms.
CONCLUSION
In the routine microbiological analyses of drugs, 
analytical methods should be validated to allow reliable 
TABLE V - Linearity values obtained of  microbial counting method for Mebendazole Oral Suspension 20 mg/mL LAFEPE® 
among the analysis groups: viability (V), peptone (P) and test (T), and respective values for Ftabulated and Fcalculated with 95% accuracy
Microorganisms Linear Coefficient  ±  SD R2 F tab F cal
Aspergillus niger ATCC 16404 V 87.85 ± 0.49 0.9872
5.14
0.87
P 73.66 ± 2.00 0.9784
T 128.57 ± 4.64 0.9854
Candida albicans ATCC 10231 V 109.47 ± 3.03 0.9694 2.23
P 102.57 ± 5.82 0.9846
T 116.62 ± 2.76 0.9932
Escherichia coli ATCC 8739 V 77.53 ± 9.83 0.9799 0.10
P 102.52 ± 8.83 0.9766
T 90.76 ± 4.28 0.9806
Pseudomonas aeruginosa ATCC 9027 V 30.94 ± 2.30 0.9788 0.21
P 43.52 ± 7.03 0.9710
T 51.38 ± 4.65 0.9544
Staphylococcus aureus ATCC 6538 V 34.79 ± 3.18 0.9773 0.55
P 39.04 ± 2.50 0.9759
T 45.38 ± 3.38 0.9853
SD = standard deviation, R ² = correlation coefficient
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results which can be interpreted satisfactorily given the 
wide variability of microorganisms involved in microbial 
analysis.
The aim of this study was to validate the microbial 
counting method in mebendazole oral suspension. The me-
thod was in accordance with the Good Laboratory Practice, 
and proved to be accurate, robust while exhibiting good 
linearity. Thus, the method was in accordance with official 
standards established for the validation of microbiologi-
cal methods and for providing reproducibility within the 
pharmaceutical industry.
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